

WHAT IS CLAIMED IS:

1. An antibody that comprises at least one amino acid sequence as listed in SEQ ID NOs:1-8 which can bind to Factor IX/Factor IXa and increase the procoagulation activity of FIXa.
5
2. The antibody according to claim 1, wherein the antibody comprises at least one complement determining region (CDR), the at least one CDR comprising at least one amino acid sequence as listed in SEQ ID NOs:3-8.
- 10 3. The antibody according to claim 2, wherein the antibody comprises at least three CDRs (CDR1, CDR2 and CDR3) that are embedded in four framework regions, wherein one or more of the at least three CDRs comprise an amino acid sequence as listed in SEQ ID NOs: 3 to 8.
- 15 4. The antibody according to claim 3, wherein the antibody comprises one or more CDR3, each CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 5 and 8.
- 20 5. The antibody according to claim 3, wherein CDR1, CDR2 and CDR3 each comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-5.
- 25 6. The antibody according to claim 3, wherein CDR1, CDR2 and CDR3 each comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 6-8.
7. The antibody according to claim 2, wherein the antibody comprises at least one of the amino acid sequences listed in SEQ ID NOs: 1-2.
- 30 8. The antibody according to claim 7, wherein the antibody comprises both of the amino acid sequences listed in SEQ ID NOs:1-2.

9. The antibody according to claim 1, which is an IgG antibody.
10. The antibody according to claim 1, which is a monoclonal antibody.
- 5 11. The antibody according to claim 1, which is an antibody fragment.
12. The antibody according to claim 1, which is a recombinant antibody.
13. The antibody according to claim 12, which is a single chain antibody.
- 10 14. The antibody according to claim 1, which is a humanized antibody.
15. The antibody of claim 1, wherein the antibody is labeled.
- 15 16. A cell expressing an antibody of claim 1.
17. The cell according to claim 16, wherein the antibody comprises at least one complement determining region (CDR), the at least one CDR comprising at least one amino acid sequence as listed in SEQ ID NOs:3-8.
- 20 18. A nucleic acid encoding the antibody of claim 1.
19. The nucleic acid according to claim 18, wherein the antibody comprises at least one complement determining region (CDR), the at least one CDR comprising at least one amino acid sequence as listed in SEQ ID NOs:3-8.
- 25 20. A method of producing an antibody that can bind Factor IX/IXa comprising culturing a cell of claim 16.
- 30 21. A method of producing an antibody that can bind Factor IX/IXa comprising expressing the nucleic acid of claim 18 in a cell.
22. A pharmaceutical composition comprising an antibody of claim 1 and a pharmaceutically acceptable carrier and/or diluent.

23. The pharmaceutical composition of claim 22, wherein the antibody comprises at least one complement determining region (CDR), the at least one CDR comprising at least one amino acid sequence as listed in SEQ ID NOs:3-8.

5

24. The pharmaceutical composition according to claim 23, further comprising factor IX, factor IX α , factor IX β and/or factor IX α .

10 25. A method for treating a patient afflicted with a blood coagulation disorder comprising administering a pharmaceutically effective amount of an antibody of claim 1 to the patient.

15 26. The method of claim 25, wherein the antibody comprises at least one complement determining region (CDR), the at least one CDR comprising at least one amino acid sequence as listed in SEQ ID NOs:3-8.

27. The method of claim 26, wherein the blood coagulation disorder is hemophilia A or hemorrhagia diathesis.